For babies & children - Scientific Research
Research on OptiBac Probiotics 'For babies & children'
Cazzola, M. et al. (2010)Immunomodulatory impact of synbiotic in TH1 and TH2 models of infection; Therapeutic Advances in Respiratory Disease 0(0) pp. 1-13
Cazzola, M. et al. (2010) Efficacy of a synbiotic supplementation in the prevention of common diseases in children: a randomized, double-blind, placebo-controlled pilot study; Therapeutic Advances in Respiratory Disease 0(0) pp. 1-8
OptiBac Probiotics For babies & children reducing childhood infections - May 2009
The Institut Rosell led a randomised, double-blind, placebo-controlled study on OptiBac Probiotics 'For babies & children' (For your child’s health), finding that the combination of probiotics and prebiotics could reduce the incidence of infant infections by 25%. The synbiotic was found to reduce the incidence of Ear-nose-throat (ENT), bronchopulmonary or gastric disorder in children during the winter season. We've talked more about this clinical trial in our FAQ click here to read more.
Source: Cazzola, M. et al. (2010) Efficacy of a synbiotic supplementation in the prevention of common diseases in children: a randomized, double-blind, placebo-controlled pilot study; Therapeutic Advances in Respiratory Disease 0(0) pp. 1-8
A multi-centre randomized, double-blind, placebo-controlled study of 221 healthy infants was conducted by the University of Madrid, looking at the safety and tolerance of the three strains of bacteria in 'For babies & children' (Bifidobacterium infantis Rosell-33,Lactobacillus acidophilus Rosell-52 and Bifidobacterium bifidum Rosell-71). The infants were divided in to four groups and each group was given either one of the three strains of probiotic bacteria or a placebo for an eight week intervention period. (Dosage used in the probiotic group was 3 Billion cfu). The study collected data on growth of the infants (weight, height and head circumference), any adverse events (AEs) or serious adverse events (SAE's), amounts of D-lactic acid in urine samples and stool characteristics. The results showed that changes in growth measurements were the same across all four groups, as were the incidence of adverse and serious adverse events. The study concluded that these three strains of bacteria are safe and well-tolerated in infancy.
Manzano, S. et al. (2017) Safety and tolerance of three probiotic strains in healthy infants: a multi-centre randomized, double-blind, placebo-controlled trial; Beneficial Microbes, 2017 online.
Source: Beneficial Microbes on-line, 2017. 'Safety and tolerance of three probiotic strains in healthy infants: a multi-centre randomized, double-blind, placebo controlled trial'. Authors: S.Manzano, J.De Andres, I. Castro, J.M Rodriguez, E. Jimenez and I. Espinosa-Martos.Study shows 'For babies & children' reduces asthma symptoms in children
This clinical trial found that the frequency of respiratory infections and wheezing in children, with and without asthma, significantly decreased after 3 months of supplementing with the synbiotic supplement1. Children would typically experience an infection at least once per month, but after 3 months of taking this probiotic it became a rare occurrence; after 6 months, infection and wheezing rate was under control with no incidence recorded for any of the children. These results were maintained with supplementation 9 months into the trial. The table below reflects the results.
There was also a progressive increase in the total IgA serum and a decrease in IgE serum which was maintained during supplementation with the synbiotic. IgE has been known to play a crucial role in mediating allergic reactions and asthma. Low levels of IgA during childhood has been associated with a higher risk of developing asthma and allergies. Click here to read more about the clinical trial.
Source: Stojkovic, A., & Simovic, M. A. (2016). Clinical trial/experimental study (consort compliant): Optimal time period to achieve the effects on synbiotic-controlled wheezing and respiratory infections in young children. Serbian Journal of Management, 38-43.
Clinical Research on Probiotics & Prebiotics and Infants & Children
The trials summarised and listed below include studies on the families and species of bacteria as found in OptiBac Probiotics 'For babies & children', as well as on the prebiotic in 'For babies & children', Fructooligosaccharides (FOS). Please note that not all of these trials listed are on the exact strains in the product. For finished product trials please scroll up.
Eczema in infants, and diversity of gut bacteria - September 2008
Infants with eczema were found to have less variation in their gut microbiota than babies without eczema, according to a small study at Harvard by Forno et al.
The entire study can be accessed at the following link - http://www.clinicalmolecularallergy.com/content/6/1/11
Probiotics and prebiotics in the prevention of eczema in infants - October 2007
Australian researchers analysed 12 studies covering 2,000 infants to find that probiotics such as Lactobacillus rhamnosus, and prebiotics such as GOS and FOS demonstrated benefits for various allergic and atopic diseases, and food intolerances. The majority of the studies analysed for this report administered probiotics during the mother’s pregnancy or when breastfeeding, or added probiotics to infant formula for the first six months.
Source: Cochrane Database of Systematic Reviews 2007, Issue 4. "Prebiotics in infants for prevention of allergic disease and food hypersensitivity" Authors: D.A. Osborn, J.K. Sinn
Probiotics and childhood constipation - August 2007
A pilot study by Bekkali et al analysed the benefits of probiotic species including Bifidobacteria bifidum, Bifidobacteria infantis and Lactobacillus rhamnosus in children aged 4-16 years who were suffering from constipation. The probiotics generally resulted in an increased amount of bowel movements and a decrease in faecal incontinence, as well as less abdominal pain.
The study can be read at http://www.nutritionj.com/content/6/1/17
Probiotics and premature babies - May 2007
An analysis of various studies covering more than 1000 infants given different probiotic supplements found a reduced risk of necrotising enterocolitis in babies given probiotics as opposed to those on placebos. The report also stated a 53% reduction in the risk of mortality. Babies administered with probiotics were found to be 74% less at risk of developing necrotising enterocolitis - one of the commonest gastrointestinal diseases in premature infants.
Source: The Lancet. 12-18 May 2007, Volume 369, Issue 9573, Pages 1614-1620. "Probiotics for prevention of necrotising enterocolitis in preterm neonates with very low birth weight: a systematic review of randomised controlled trials"
Probiotics & Prebiotics in infant formula, fewer infections and less constipation - January 2007
A study by Nestle found that formula with Bifidobacterium longum and the prebiotics GOS and FOS was beneficial to the general health of infants. The study covered 138 infants and gave each of them either a synbiotic mix (with both prebiotics and probiotics) in their formula, or a placebo control. The conclusion was that children with the synbiotic mix had less incidences of constipation, as well as less infections of the respiratory tract.
Source: Nutrition January 2007, Volume 23, Issue 1, Pages 1-8 "Clinical evaluation of a new starter formula for infants containing live Bifidobacterium longum BL999 and prebiotics" Authors: G. Puccio, C. Cajozzo, F. Meli, F. Rochat, D. Grathwohl and P. Steenhout
Prebiotics and childhood infections - October 2006
A small study at the Paris Université René Descartes involving 35 healthy children administered either oligofructose (FOS) or a maltodextrin placebo for a period of 21 days. Children given the prebiotics were found to have increased Bifidobacteria in the faeces, and significantly decreased levels of the potentially harmful bacteria, Clostridia. They also caught fewer infectious diseases, and demonstrated less flatulence, diarrhoea, vomiting and fever when compared to the children given the placebo.
Van Niel, C. W. et al (2002). Lactobacillus therapy for acute infectious diarrhea in children: a meta-analysis. Pediatrics. Vol. 109 pp. 678 – 684
Marschan, E. et al. (2008). Probiotics in infancy induce protective immune profiles that are characteristic for chronic low-grade inflammation; Clinical and Experimental Allergy – the Journal of the British Society of Allergy and Clinical Immunology; Feb 11
Rautava, S. et al (2002). ‘Probiotics during pregnancy and breast-feeding might confer immunomodulatory protection against atopic disease in the infant’. Journal of Allergy and Clinical Immunology, Jan Vol. 109 (1), pp. 119-121
Rosenfeldt. V, et al (2002) Effect of probiotic Lactobacillus strains in young children hospitalized with acute diarrhea. Pediatr Infect Dis J;21 :411 –416
Knol J. et al. (2005) Colon microflora in infants fed formula with galacto- and fructo-oligosaccharides: more like breast-fed infants. Journal of pediatric gastroenterology and nutrition. Jan; Vol. 40 (1) pp.36 - 42
Saavedra, J.M. et al. (1994) Feeding of Bifidobacterium bifidum and Streptococcus thermophilus to infants in hospital for prevention of diarrhoea and shedding of rotavirus. The Lancet. Oct 15;344(8929):1046-9.
Saavedra, J.M, et al. (1989) Long-term consumption of infant formulas containing live probiotic bacteria: tolerance and safety: American Journal of Clinical Nutrition: Vol. 79. pp. 261-267
Fukushima, Y. et al (1998). Effect of a probiotic formula on intestinal immunoglobulin A production in healthy children. International Journal of Food Microbiology. Vol. 42 (1-2), pp. 39 - 44
Zajewska, H. & Mrukowicz, J.Z. (2001) Probiotics in the treatment and prevention of acute infectious diarrhea in infants and children: a systematic review of published randomized, double-blind, placebo-controlled trials. J Pediatr Gastroenterol Nutr;33(suppl 2) :S17 –S25)
Langhendries, J.P et al. (1995) Effect of fermented infant formula containing viable bifidobacteria on the fecal flora composition and pH of healthy full-term infants: J Pediatr Gastroenterol Nutr, 21, 2, 177081